Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations.
EGFR
NSCLC
TKIs
chemotherapy
mutations
oligoprogression
oncogene-addicted
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Feb 2022
06 Feb 2022
Historique:
received:
17
01
2022
revised:
02
02
2022
accepted:
03
02
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
After a variable period of activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment, patients with advanced non-small cell lung cancer (NSCLC) harboring
Identifiants
pubmed: 35159099
pii: cancers14030832
doi: 10.3390/cancers14030832
pmc: PMC8834352
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Am J Cancer Res. 2017 Apr 01;7(4):962-972
pubmed: 28469968
Eur J Cancer. 2017 Jan;70:12-21
pubmed: 27866095
Lung Cancer. 2013 Mar;79(3):276-82
pubmed: 23261231
Oncologist. 2013;18(11):1214-20
pubmed: 24072220
Ann Oncol. 2020 Apr;31(4):507-516
pubmed: 32139298
J Thorac Oncol. 2021 Feb;16(2):250-258
pubmed: 33122107
J Clin Oncol. 2021 Mar 20;39(9):1040-1091
pubmed: 33591844
Invest New Drugs. 2021 Apr;39(2):477-487
pubmed: 33052556
J Thorac Oncol. 2012 Nov;7(11):1722-7
pubmed: 23059777
Future Oncol. 2022 Mar;18(9):1039-1054
pubmed: 34918545
J Clin Oncol. 2006 Sep 20;24(27):4517-20
pubmed: 16983123
J Clin Oncol. 2017 Dec 20;35(36):4027-4034
pubmed: 28968167
Lancet Respir Med. 2020 Nov;8(11):1132-1143
pubmed: 32479794
Cancer Lett. 2017 Jan 28;385:51-54
pubmed: 27840244
Innovation (Camb). 2021 Apr 03;2(2):100103
pubmed: 34557754
J Clin Oncol. 2018 Aug 28;:JCO2018783118
pubmed: 30153097
Cancer Discov. 2019 Jul;9(7):926-943
pubmed: 31092401
J Clin Oncol. 2010 Jan 10;28(2):357-60
pubmed: 19949011
Expert Opin Investig Drugs. 2020 Apr;29(4):363-372
pubmed: 32073317
Curr Oncol. 2019 Feb;26(1):e81-e93
pubmed: 30853813
Lancet Oncol. 2020 Mar;21(3):373-386
pubmed: 32027846
Clin Cancer Res. 2010 Dec 1;16(23):5873-82
pubmed: 21030498
Oncologist. 2022 Mar 4;27(2):87-e115
pubmed: 35641222
CA Cancer J Clin. 2017 Mar;67(2):138-155
pubmed: 28140453
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
Biochem Biophys Res Commun. 2018 Jul 20;502(3):332-337
pubmed: 29802850
Lancet Oncol. 2015 Aug;16(8):990-8
pubmed: 26159065
J Thorac Oncol. 2022 Mar;17(3):411-422
pubmed: 34801749
Biomark Res. 2019 Nov 21;7:27
pubmed: 31832192
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Lung Cancer. 2013 Mar;79(3):283-8
pubmed: 23254265
JAMA Oncol. 2016 Mar;2(3):305-12
pubmed: 26720423
Transl Lung Cancer Res. 2021 May;10(5):2118-2131
pubmed: 34164264
Clin Lung Cancer. 2014 Jan;15(1):1-6
pubmed: 24176733
Clin Oncol (R Coll Radiol). 2019 Dec;31(12):824-833
pubmed: 31182289
Crit Rev Oncol Hematol. 2021 Oct;166:103454
pubmed: 34455092
Br J Cancer. 2019 Oct;121(9):725-737
pubmed: 31564718
J Clin Oncol. 2018 Nov 1;36(31):3101-3109
pubmed: 30156984
JCO Precis Oncol. 2021 Jan 14;1:
pubmed: 34036220